Literature DB >> 24840946

B-cell receptor signaling in lymphoid malignancies and autoimmunity.

Ana M Avalos1, Friederike Meyer-Wentrup2, Hidde L Ploegh3.   

Abstract

The B-cell receptor (BCR) for antigen is a key sensor required for B-cell development, survival, and activation. Rigorous selection checkpoints ensure that the mature B-cell compartment in the periphery is largely purged of self-reactive B cells. However, autoreactive B cells escape selection and persist in the periphery as anergic or clonally ignorant B cells. Under the influence of genetic or environmental factors, which are not completely understood, autoreactive B cells may be activated. Similar activation can also occur at different stages of B-cell maturation in the bone marrow or in peripheral lymphoid organs and give rise to malignant B cells. The pathology that typifies neoplastic lymphocytes and autoreactive B cells differs: malignant B cells proliferate and occupy niches otherwise taken up by healthy leukocytes or erythrocytes, while autoreactive B cells produce pathogenic antibodies or present self-antigen to T cells. However, both malignant and autoreactive B cells share the commonality of deregulated BCR pathways as principal contributors to pathogenicity. We first summarize current views of BCR activation. We then explore how anomalous BCR pathways correlate with malignancies and autoimmunity. We also elaborate on the activation of TLR pathways in abnormal B cells and how they contribute to maintenance of pathology. Finally, we outline the benefits and emergence of mouse models generated by somatic cell nuclear transfer to study B-cell function in manners for which current transgenic models may be less well suited.
© 2014 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Autoimmunity; B-cell malignancies; B-cell receptor; BCR; Leukemia; Lupus; Lymphoma; SCNT; Somatic cell nuclear transfer; Transnuclear mice

Mesh:

Substances:

Year:  2014        PMID: 24840946     DOI: 10.1016/B978-0-12-800266-7.00004-2

Source DB:  PubMed          Journal:  Adv Immunol        ISSN: 0065-2776            Impact factor:   3.543


  15 in total

Review 1.  The early history of B cells.

Authors:  Max D Cooper
Journal:  Nat Rev Immunol       Date:  2015-02-06       Impact factor: 53.106

Review 2.  Three newly approved drugs for chronic lymphocytic leukemia: incorporating ibrutinib, idelalisib, and obinutuzumab into clinical practice.

Authors:  David S Sanford; William G Wierda; Jan A Burger; Michael J Keating; Susan M O'Brien
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2015-02-19

Review 3.  Genetics and pathogenesis of systemic lupus erythematosus and lupus nephritis.

Authors:  Chandra Mohan; Chaim Putterman
Journal:  Nat Rev Nephrol       Date:  2015-03-31       Impact factor: 28.314

Review 4.  Chronic lymphocytic leukemia therapy: new targeted therapies on the way.

Authors:  Candida Vitale; Jan A Burger
Journal:  Expert Opin Pharmacother       Date:  2016-04-12       Impact factor: 3.889

Review 5.  B cells in chronic graft-versus-host disease.

Authors:  William McManigle; Ayman Youssef; Stefanie Sarantopoulos
Journal:  Hum Immunol       Date:  2019-03-05       Impact factor: 2.850

Review 6.  B cell checkpoints in autoimmune rheumatic diseases.

Authors:  Samuel J S Rubin; Michelle S Bloom; William H Robinson
Journal:  Nat Rev Rheumatol       Date:  2019-05       Impact factor: 20.543

Review 7.  MicroRNA regulation of B cell receptor signaling.

Authors:  Timothy C Borbet; Marcus J Hines; Sergei B Koralov
Journal:  Immunol Rev       Date:  2021-09-14       Impact factor: 12.988

Review 8.  Polychromatic flow cytometry in evaluating rheumatic disease patients.

Authors:  Chungwen Wei; Scott Jenks; Iñaki Sanz
Journal:  Arthritis Res Ther       Date:  2015-03-05       Impact factor: 5.156

Review 9.  Role of Tyrosine Kinase Inhibitors in Indolent and Other Mature B-Cell Neoplasms.

Authors:  Nadine Kutsch; Reinhard Marks; Richard Ratei; Thomas K Held; Martin Schmidt-Hieber
Journal:  Biomark Insights       Date:  2015-08-16

Review 10.  MEF2 transcription factors: developmental regulators and emerging cancer genes.

Authors:  Julia R Pon; Marco A Marra
Journal:  Oncotarget       Date:  2016-01-19
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.